RxDoctor Payments Data

Melissa Franco, PA

Physician Assistant · Miami, FLNPI 1801161559

Payments from drug & device makers

$14,058in general payments, 2019–2025

Across 148 payments — averaging $94.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Gilead$3K
  • Madrigal Pharmaceuticals$2K
  • Ipsen Biopharmaceuticals, Inc$952
  • Novo Nordisk$765
  • Intercept Pharmaceuticals, Inc.$589
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$6,72348%
  • Speaking & faculty fees$1,2309%
  • Travel & lodging$9967%
  • Food & beverage$5,07836%
  • Education$320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,058 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$17,604
Medicare patients
115
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin178$565,415
VemlidyTenofovir Alafenamide88$150,227
Ursodiol81$11,171
Entecavir74$7,507
Mycophenolate Mofetil21$4,359
Lactulose73$2,739
CholestyramineCholestyramine (With Sugar)12$1,009
Nadolol11$426
Rosuvastatin Calcium14$270
Omeprazole22$218
Azathioprine13$184
Carvedilol43$174
Spironolactone23$142
Amiloride Hcl13$124
Propranolol Hcl11$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$4,114$565,415178 claims
GileadVemlidy$3,439$150,22788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →